Get the StoQuant digest — free

Free StoQuant digest by email. No account needed. See today's research picks.

Subscribe free

NMRA vs OVID — Stock Comparison

Compare NMRA and OVID side-by-side on StoQuant: NMRA Q-Score 19 vs OVID 51; analyst signal 67 vs 77. Plus alt data signals, insider buying, catalysts, strategic edges, short interest, social sentiment, and macro context.

Side-by-side snapshot

• NMRA — Neumora Therapeutics, Inc. Common Stock · Health Care · market cap $71M · Q-Score verdict Strong Sell (19.0, grade F) · analyst signal 67/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 88/100, valuation 74/100 · weakest signals: analyst consensus 48/100, technicals 3/100. Full NMRA research.
• OVID — Ovid Therapeutics Inc. · Health Care · market cap $422M · Q-Score verdict Hold (51.0, grade C) · analyst signal 77/100 — Wall Street ratings and target changes turned into a 0-100 score · strongest signals: competitive moat 97/100, analyst consensus 81/100 · weakest signals: valuation 74/100, technicals 41/100. Full OVID research.

What you can compare

• Q-Score: StoQuant's composite 0–100 rating based on 140+ financial signals.
• Alt data signals: Google Trends, EDGAR 8-K filings, job postings, and more.
• Insider activity: Cluster scores and recent Form 4 buying.
• Catalysts: Earnings, analyst changes, M&A, clinical trials, and SEC events.
• Strategic edges: Competitive moat and durable advantage analysis.
• Short interest & social sentiment: Short % float, social mention volume, and bullish/bearish breakdown.
• Macro context: Market regime and sector rotation alignment.

Deep dive: NMRA research · OVID research. Sign in to StoQuant to run live comparisons for any tickers. Sign up free →